Shilpa Medicare gets US FDA approval for generic Esbriet tablets

Shilpa Medicare has received US Food and Drug Administration (FDA) approval for pirfenidone tablets. The company received US FDA’s tentative approval for its ANDA, pirfenidone tablets, 267 mg and 801 mg, on January 30. The ANDA is filed as 'First to File' submission on NCE -1 date.

Pirfenidone tablets is a generic equivalent of reference listed drug (RLD) Esbriet tablets of Hoffmann La Roche Inc used in the treatment of idiopathic pulmonary fibrosis.

The annual US market for pirfenidone is approximately US$ 716.3 million, as per the IQVIA MAT Q2 2019 data.

The company also received Central Drugs Standard Control Organization (CDSCO), New Delhi permission for manufacturing and marketing of lenvatinib capsules 4mg and 10mg in India.

Lenvatinib capsules 4mg and 10mg is a generic equivalent of reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma.

Shilpa Medicare will commercialise the product under the brand name Lenshil to become the first Indian company in the country to bring the cheaper version of this drug to Indian cancer patients. Now Indian patients will get access to this breakthrough therapy at an affordable cost and manufactured in India. The presently available brand of lenvatinib mesylate in market is being imported into India.

According to IQVIA MAT Q2 2019 data, the Indian market for lenvatinib capsules 4mg and 10mg is approximately US$ 0.32 million.

 Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=120934&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more